Author:
Sergio Villanueva Baselga,Ruben Mora,Luis Villegas
Abstract
Abstract
Purpose
. While doxycycline shows promise as a preventative measure against certain STIs (post-exposure prophylaxis or PEP, and pre-exposure prophylaxis or PrEP), very few medical and scientific associations favor its community use. Nevertheless, sexual health organizations for gay, bisexual and other men who have sex with men (GBMSM) community have noticed an increase in requests of its use.
Methods
. The sexual health organization “Stop Sida” in Spain launched an anonymous snapshot survey to evaluate the current use of doxycycline as prevention strategy (both PEP and PrEP) in Spain through its social networks and its support groups in telegram.
Results
. 150 valid answers were obtained from different parts of Spain. 82 respondents (54,6% of total) had ever taken doxycycline, out of which 29 (35,4%) indicated the use as doxy-PEP and 7 (8,5%) as doxy-PrEP. The self-reported rate of STI diagnoses (mainly of syphilis and chlamydia) in the past 12 months was lower among those participants who reported having used doxy-PEP compared with those who did not report using doxy-PEP. The most common ways to obtain the doxycycline were telling a specialist that they have had a risky contact or by using leftover pills from a previous treatment.
Conclusion
The current study is the first study to describe the use of doxycycline as a preventive strategy among the GBMSM community in Spain, and the first designed, launched and analyzed entirely by an NGO dealing with sexual health for the GBMSM community. The results obtained are aligned with other studies in other parts of Europe, such as Germany.
Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018;18:308–17.
2. Luetkemeyer AF, Donnell D, Dombrowski JC, Cohen S, Grabow C, Brown CE, et al. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med. 2023;388(14):1296–306. https://doi.org/10.1056/NEJMoa2211934.
3. Molina JM, Bercot B, Assoumou L, Algarte-Genin M, Rubenstein E, Pialoux G et al. Conference on Retroviruses and Opportunistic Infections (CROI). ANRS 174 DOXYVAC: An open-label randomized trial to prevent STIs in MSM on PrEP. Seattle: CROI. 19–22 Feb 2023.
4. Bolan RK, Beymer MR, Weiss RE, Flynn RP, Leibowitz AA, Klausner JD. Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high-risk sex: a randomized, controlled pilot study. Sex Transm Dis. 2015;42(2):98–103. https://doi.org/10.1097/OLQ.0000000000000216.
5. European AIDS Clinical Society (EACS). Guidelines version 12.0. Brussels: EACS. Oct 2023. https://www.eacsociety.org/media/guidelines-12.0.pdf.